Format

Send to

Choose Destination
Am J Transplant. 2016 Apr;16(4):1094-101. doi: 10.1111/ajt.13582. Epub 2016 Jan 5.

Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward.

Author information

1
Departments of Surgery and Immunology, von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
2
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA.
3
Department of Medicine, University of Cincinnati School of Medicine, Cincinnati, OH.
4
Departments of Medicine and Surgery, Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.

Abstract

The development of new immunosuppressive drugs has slowed markedly over the past several years, and the outlook that improved therapy will be available to the next generation of transplant recipients is bleak. In this viewpoint, the authors outline some of important barriers to new drug development and suggest specific steps that the transplant community can take to overcome them.

KEYWORDS:

editorial/personal viewpoint; ethics and public policy Discipline

PMID:
26730885
DOI:
10.1111/ajt.13582
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center